Frontiers of cardiovascular polypills: From atherosclerosis and beyond
Sonali R Gnanenthiran, Anubha Agarwal, Anushka Patel, Sonali R Gnanenthiran, Anubha Agarwal, Anushka Patel
Abstract
Fixed-dose combination (FDC) therapies (also known as polypills) remain underutilized in clinical practice despite over two decades of evidence from randomized controlled trials demonstrating increased adherence to multidrug therapy, improved cardiovascular disease (CVD) risk factor control, and lower incidence of cardiovascular events. Evidence demonstrates that FDC-based implementation strategies can substantially complement and augment current strategies for CVD risk prevention globally. The next decade is likely to extend the frontier of cardiovascular FDC therapies, particularly given expected advances in FDC manufacturing technology and accessibility. FDC-based anti-hypertensive therapies are emerging as integral components of a pragmatic blood pressure lowering strategy. Cardiovascular FDCs are rapidly approaching its coming of age, transforming from heavily hyped research tools to pragmatic clinical instruments. This review evaluates the current evidence for cardiovascular FDCs, barriers to current use, and potential next generation advances.
Keywords: Atherosclerosis; Cardiovascular disease; Fixed dose combination; Hypertension; Polypill; Prevention.
Conflict of interest statement
Declaration of Competing Interest: George Health Enterprises, a part-owned commercial arm of The George Institute for Global Health, has received investment funds to develop fixed-dose combination products containing aspirin, statin, and blood pressure lowering drugs and has submitted a patent for the treatment of hypertension. AA plans to submit a patent for heart failure polypills.
Copyright © 2021. Published by Elsevier Inc.
Figures
Source: PubMed